India to Peru: Insulin Export Trade Route

The India to Peru Insulin corridor is one of India's established pharmaceutical export routes, with 25 shipments documented worth a combined $2.0M USD. The route is dominated by WOCKHARDT LIMITED, which alone accounts for roughly 88% of all export value, reflecting the consolidated nature of India's insulin manufacturing sector.

Across 2 active suppliers, the average shipment value stands at $81.2K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 80% of all shipments, consistent with insulin's non-urgent bulk-order profile.

Shipment activity peaks during July–September, with an average transit time of 24 days port-to-port. The route has recorded an annual growth rate of 26.9%, placing it at rank #1 among India's top insulin export destinations globally.

On the import side, key buyers of Indian insulin in Peru include PHARMARIS PERU S.A.C., PHARMARIS PERU S A C, PHARMARIS PERU S.A.C. and 1 others. PHARMARIS PERU S.A.C. is the single largest importer with 13 shipments valued at $1.5M USD.

India's insulin exports to Peru are driven primarily by a handful of large-scale manufacturers. WOCKHARDT LIMITED with 20 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 2 active exporters signals a competitive but concentrated market — buyers in Peru benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — WOCKHARDT LIMITED, WOCKHARDT LIMITED — together account for 100% of total trade value on this route. The average shipment value of $81.2K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as glaritus 10ml vial (insulin glargine 100iu/ml solution for injection 10ml) and glaritus 10ml vial (insulin glargine 100iu/ml solution for injection, 10ml), suggesting that buyers in Peru tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, PHARMARIS PERU S.A.C. is the largest importer with 13 shipments worth $1.5M USD — representing 73% of all insulin imports from India on this route.